Our results shown here are consistent with prior reports12, 28 and confirm the predictive role of the CD68+/CD8+ ratio in somatotroph adenomas naïve to SRL therapy at surgery and suggest that the prognostic role of the CD68+/CD8+ ratio should be evaluated with caution in patients pretreated with SRLs before surgery. The gene discussed is CD68; the disease is growth hormone-secreting pituitary adenoma.